Provides clients with broad range of standardized lab testing services and capabilities WILMINGTON, N.C. (April 20, 2015) – Pharmaceutical Product Development LLC (PPD) has opened a central laboratory in Shanghai, China, to deliver global scientific and technical laboratory expertise to meet growing client demand for these services in China. The new facility, which has been […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
-Technology and Industry Leader to Head eClinical Business Unit- NEWTOWN, PENNSYLVANIA, April 20, 2015 – BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that Mukhtar Ahmed, a recognized business leader within the life sciences, healthcare and technology sectors, will join BioClinica on April 20th as President of its Global eClinical […]
(Reuters) – Eli Lilly and Co said its experimental drug, ixekizumab, reduced the signs and symptoms of active psoriatic arthritis in patients more than a placebo did in a late-stage trial. Up to 30 percent of psoriasis patients develop psoriatic arthritis, an inflammatory form of arthritis that can cause swelling, stiffness and pain in and around […]
(Reuters) – A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday. The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared […]
PHILADELPHIA–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced the presentation of data on two epigenetic targets in its pioneering therapeutic pipeline. These data were presented this week at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, Penn. Epizyme’s AACR 2015 posters […]
(Reuters) – Mindfulness-based cognitive therapy (MBCT) may be just as effective as anti-depressants in helping prevent people with chronic depression from relapsing, scientists said on Tuesday. Depression is one of the most common forms of mental illness, affecting more than 350 million people worldwide. It is ranked by the World Health Organization as the leading […]
The 49-year-old woman had had three melanoma growths removed from her skin, but now the disease was spreading further. A several-centimeter-sized growth under her left breast went deep into her chest wall. Some of the tissue in the tumor was dying because of lack of blood flow. Doctors at Memorial Sloan Kettering Cancer Center offered […]
Tokai Pharmaceuticals Announces Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth
BOSTON–(BUSINESS WIRE)–Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and […]
PORTLAND, Ore., April 20, 2015 /PRNewswire/ — Research published today in the Proceedings of the National Academy of Sciences (PNAS) demonstrates that technology invented by researchers at Oregon Health & Science University’s Casey Eye Institute can improve the clinical management of the leading causes of blindness. Optical coherence tomography (OCT) angiography could largely replace current dye-based […]
(Reuters) – A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose of the experimental product to prove effectiveness, according to data presented at a cancer meeting on Sunday. The so-called […]